Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602) Meeting Abstract
| Authors: | Strosberg, J. R.; Zemla, T. J.; Geyer, S. M.; Knopp, M. V.; Behr, S.; Pulsipher, S.; Acoba, J. D.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; Konda, B.; Trikalinos, N.; Tawfik, B.; Raj, N. P.; Shaheen, S.; Vijayvergia, N.; Dasari, A.; O'Reilly, E. M.; Meyerhardt, J. A.; Chan, J. A. |
| Abstract Title: | Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602) |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.666 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting Abstract: 666 -- Source: CINAHL Plus with Full Text |
Altmetric
Citation Impact
BMJ Impact Analytics
